New drugs in neoadjuvant breast cancer therapy - European Medical Journal

New drugs in neoadjuvant breast cancer therapy

Oncology
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Sibylle Loibl (German Breast Group, Neu-Isenburg, Germany) discusses recent advances in neoadjuvant therapy for breast cancer, including the rationale for the use of the surrogate endpoint, pathological complete response (pCR), for survival in neoadjuvant studies.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>